ArticleThe European respiratory journal2017
Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation.
Article in The European respiratory journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- BMI is associated with FEVRespiratory research · 2019Pooled it
- Proteome-wide Mendelian randomisation of lung function to identify potential therapeutic targets for respiratory disease.ERJ open research · 2026Article
- Functionally informed cis and trans proteome-wide association studies prioritize disease-critical genes.Research square · 2026Article
- Functionally informed cis and trans proteome-wide association studies prioritize disease-critical genes.medRxiv : the preprint server for health sciences · 2026Article
- Pilot proteomics study for identifying a pollution exposure signature in firefighters.Journal of exposure science & environmental epidemiology · 2026Article
- Article
- Effect of oral treatment with quercetin on inflammatory and oxidative stress markers in patients with chronic obstructive pulmonary disease.Pharmacological research. Natural products · 2025Article
- Diagnostic Challenges and Pathogenetic Differences in Biomass-Smoke-Induced versus Tobacco-Smoke-Induced COPD: A Comparative Review.Diagnostics (Basel, Switzerland) · 2024Review
- Pulmonary surfactant and prostaglandin EPhysiological reports · 2024Article
- Interplay between host humoral pattern recognition molecules controls undue immune responses against Aspergillus fumigatus.Nature communications · 2024Article
- Exome-wide evidence of compound heterozygous effects across common phenotypes in the UK Biobank.Cell genomics · 2024Article
- Multi-omics analysis of diabetic pig lungs reveals molecular derangements underlying pulmonary complications of diabetes mellitus.Disease models & mechanisms · 2024Article
- Club cell-specific telomere protection protein 1 (TPP1) protects against tobacco smoke-induced lung inflammation, xenobiotic metabolic dysregulation, and injurious responses.FASEB bioAdvances · 2024Article
- Surfactant protein D prevents mucin overproduction in airway goblet cells via SIRPα.Scientific reports · 2024Article
- Proteomic associations with forced expiratory volume: a Mendelian randomisation study.Respiratory research · 2024Article
- Serum levels of HMW adiponectin and its receptors are associated with cytokine levels and clinical characteristics in chronic obstructive pulmonary disease.Open medicine (Warsaw, Poland) · 2024Article
- Exploring the associations between elevated plasma SP-D levels and OSCAR gene expression as potential biomarkers in patients with COPD: a cross-sectional study.Frontiers in pharmacology · 2024Article
- Molecular Impact of Conventional and Electronic Cigarettes on Pulmonary Surfactant.International journal of molecular sciences · 2023Review
- Exome-wide evidence of compound heterozygous effects across common phenotypes in the UK Biobank.medRxiv : the preprint server for health sciences · 2023Article
- Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder.The Lancet. Respiratory medicine · 2022Review
Corrections and comments
- Commented on by
Authors and funding
25 authors at 10 institutions in 4 countries.
Funding
Abstract
Surfactant protein D (SP-D) is produced primarily in the lung and is involved in regulating pulmonary surfactants, lipid homeostasis and innate immunity. Circulating SP-D levels in blood are associated with chronic obstructive pulmonary disease (COPD), although causality remains elusive.In 4061 subjects with COPD, we identified genetic variants associated with serum SP-D levels. We then determined whether these variants affected lung tissue gene expression in 1037 individuals. A Mendelian randomisation framework was then applied, whereby serum SP-D-associated variants were tested for association with COPD risk in 11 157 cases and 36 699 controls and with 11 years decline of lung function in the 4061 individuals.Three regions on chromosomes 6 (human leukocyte antigen region), 10 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.